What is the 13F Pro Quality Score for RKDA?

13F Pro ranks Arcadia Biosciences, Inc. (RKDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RKDA's current score at https://13fpro.ai/research/RKDA (free sign-up required for the full ranking).

Which hedge funds own the most RKDA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RKDA include ARMISTICE CAPITAL,, SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RKDA as soon as new 13F filings post.

Where does 13F Pro source RKDA data?

All Arcadia Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcadia Biosciences, Inc. files with the SEC under CIK 1469443. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RKDA in?

Arcadia Biosciences, Inc. (RKDA) is classified in the Energy sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/energy.

How often is RKDA research updated on 13F Pro?

RKDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcadia Biosciences, Inc.(RKDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Energy →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1469443 RKDA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $8.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RKDA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Arcadia Biosciences, Inc. (RKDA), a Energy sector company. RKDA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $8.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Arcadia Biosciences, Inc. reports quarterly revenue of $1.1M, net income of $-4.4M, free cash flow of $-1.1M. Top institutional holders of RKDA by reported 13-F value include ARMISTICE CAPITAL,, SABBY MANAGEMENT,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. RKDA trades on the Nasdaq exchange and files with the SEC under CIK 1469443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RKDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcadia Biosciences, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$1.1M

Net Income

Q1 2026

$-4.4M

Free Cash Flow

Q1 2026

$-1.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.7% YoY

$4.9MFY 2025

FY21 $6.8MFY22 $7.4MFY24 $5.0MFY25 $4.9M

Net Income

+66.8% YoY

$-2.3MFY 2025

FY21 $-14.7MFY22 $-15.4MFY24 $-7.0MFY25 $-2.3M

Operating Income

+31.5% YoY

$-2.5MFY 2025

FY21 $-35.5MFY22 $-14.0MFY24 $-3.6MFY25 $-2.5M

EPS (Diluted)

+66.9% YoY

$-1.71FY 2025

FY21 $-27.56FY22 $-25.65FY24 $-5.17FY25 $-1.71

Total Assets

-51.6% YoY

$6.5MFY 2025

FY21 $43.9MFY22 $28.9MFY24 $13.5MFY25 $6.5M

Total Debt

—FY 2025

FY21 $0.00FY22 —FY24 —FY25 —

Op. Cash Flow

+51.0% YoY

$-4.7MFY 2025

FY21 $-25.9MFY22 $-14.0MFY24 $-9.6MFY25 $-4.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2018	FY 2016
Revenue	$4.9M -3.7%	$5.0M -32.0%	$7.4M +9.4%	$6.8M +363.1%	$1.5M -54.1%	$3.2M
Net Income	$-2.3M +66.8%	$-7.0M +54.2%	$-15.4M -4.9%	$-14.7M -8.8%	$-13.5M +31.3%	$-19.6M
Operating Income	$-2.5M +31.5%	$-3.6M +74.0%	$-14.0M +60.6%	$-35.5M -110.6%	$-16.9M +9.4%	$-18.6M
EPS (Diluted)	$-1.71 +66.9%	$-5.17 +79.8%	$-25.65 +6.9%	$-27.56	—	—
Total Assets	$6.5M -51.6%	$13.5M -53.3%	$28.9M -34.1%	$43.9M +82.8%	$24.0M -57.5%	$56.6M
Total Debt	—	—	—	$0.00	$0.00 -100.0%	$25.1M
Operating Cash Flow	$-4.7M +51.0%	$-9.6M +31.3%	$-14.0M +46.0%	$-25.9M -90.0%	$-13.6M	—

AI Insight: RKDA Financial Trends

RKDA faces persistent cash burn and collapsing equity with no revenue growth or profitability path visible.

• Revenue flat at $1M across all eight quarters; no top-line traction since Q2 2024.

• Operating cash flow deteriorated from -$2M in Q2 2024 to -$1M in Q1 2026; burn persists despite scaling back.

• Equity eroded 50% from $12M (Q2 2024) to unavailable in Q1 2026; net income swung wildly between -$4M and +$3M.

⚠ Equity data missing Q1 2025–Q1 2026; company may have breached solvency or triggered capital restructuring.

⚠ Net income volatility (range: -$4M to +$3M) suggests inconsistent or non-repeatable earnings; operating losses dominate.

AI Insight: RKDA Ratio Trends

Arcadia is unprofitable with severe margin volatility; no clear path to sustainable returns visible in trailing twelve months.

• Operating margin ranged from +44.2% (Q1 2025) to -187.4% (Q4 2024), indicating extreme quarterly swings and lack of operational consistency.

• TTM operating margin stands at -80.0% and TTM net profit margin at -195.9%, reflecting sustained unprofitability over the last year.

• ROA deteriorated to -81.6% in Q4 2025, the worst quarter recorded, after briefly positive 80.0% in Q1 2025.

⚠ Exceptional volatility in both operating and net margins across all periods suggests potential accounting adjustments, write-downs, or one-time items masking core operations.

⚠ Latest quarter (Q1 2026) shows -70.8% operating margin; insufficient data to determine if stabilization or continued deterioration.

Get alerted when RKDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcadia Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RKDA

ARMISTICE CAPITAL, LLC
$220.0K159,390 sh
SABBY MANAGEMENT, LLC
$158.1K114,554 sh
GEODE CAPITAL MANAGEMENT, LLC
$43.8K31,743 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$17.4K12,614 sh
STATE STREET CORP
$16.8K12,146 sh
VANGUARD CAPITAL MANAGEMENT LLC
$13.3K9,644 sh
VANGUARD FIDUCIARY TRUST CO
$6.1K4,394 sh
Tower Research Capital LLC (TRC)
$5.4K3,940 sh
UBS Group AG
$1.1K807 sh
SBI Securities Co., Ltd.
$166.00120 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$220.0K	159,390
SABBY MANAGEMENT, LLC	$158.1K	114,554
GEODE CAPITAL MANAGEMENT, LLC	$43.8K	31,743
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$17.4K	12,614
STATE STREET CORP	$16.8K	12,146
VANGUARD CAPITAL MANAGEMENT LLC	$13.3K	9,644
VANGUARD FIDUCIARY TRUST CO	$6.1K	4,394
Tower Research Capital LLC (TRC)	$5.4K	3,940
UBS Group AG	$1.1K	807
SBI Securities Co., Ltd.	$166.00	120

More Energy Companies

View all Energy →

ACDC

ProFrac Holding Corp.

AESI

Atlas Energy Solutions Inc.

AGIG

ABUNDIA GLOBAL IMPACT GROUP, INC.

Antero Midstream Corp

AMPY

Amplify Energy Corp.

AMR

Alpha Metallurgical Resources, Inc.

ANNA

AleAnna, Inc.

APA

APA Corp

Put RKDA on your watchlist

Track score changes the day Arcadia Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RKDA a good stock to buy?

13F Pro's AI-powered analysis of Arcadia Biosciences, Inc. (RKDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Energy sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RKDA are available on the RKDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RKDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RKDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcadia Biosciences, Inc.'s investment landscape.